Abstract
Kinpeygo (budesonide) is a corticosteroid‐based therapy approved for the treatment of adults with rapidly progressing primary immunoglobulin A nephropathy. This article discusses its mode of action, efficacy and adverse effects.
Reference8 articles.
1. IgA nephropathy
2. An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
3. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
4. NICE. Targeted‐release budesonide for treating primary IgA nephropathy. 2023. Available from:https://www.nice.org.uk/guidance/ta937.
5. Product information. 2022 European Medicines Agency. Kinpeygo (budesonide)